Resolution of Hydronephrosis in a Patient With Mucopolysaccharidosis Type II With Enzyme Replacement Therapy

Urology. 2017 Mar:101:163-165. doi: 10.1016/j.urology.2016.12.010. Epub 2016 Dec 20.

Abstract

Mucopolysaccharidosis type II (MPS II) is caused by deficiency of lysosomal enzyme iduronate-2-sulfatase. Insufficient activity of the enzyme results in accumulation of glycosaminoglycans leading to progressive multisystem pathologies. MPS II is less likely to be complicated by kidney and urinary tract problems. We report a boy with MPS II, who developed left hydronephrosis. His hydronephrosis improved after starting enzyme replacement therapy. It was suggested that MPS II was closely associated with the pathogenesis of hydronephrosis.

Publication types

  • Case Reports

MeSH terms

  • Biomarkers / blood
  • Child
  • Enzyme Replacement Therapy / methods*
  • Humans
  • Hydronephrosis / diagnosis
  • Hydronephrosis / drug therapy*
  • Hydronephrosis / etiology
  • Male
  • Mucopolysaccharidosis II / complications
  • Mucopolysaccharidosis II / drug therapy*
  • Mucopolysaccharidosis II / enzymology

Substances

  • Biomarkers